FDA’s Combination Product Review Process: How It Looks Inside The Agency
This article was originally published in RPM Report
Biopharma sponsors have precious little to complain about in the current new drug review process, but one area of concern has been uncertainty around combination product reviews. Once limited to diabetes and pulmonary drugs, device-related consults are much more common. FDA conducted its own internal review of the issues – and the findings suggest that the perceptions of sponsors are not far from those of FDA managers. The agency says it is making progress already on improving lines of communications. Here is the report.
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.